Salvia BioElectronics B.V.

Salvia BioElectronics operates at the intersection of medical devices, clinical therapeutics, and bioelectronics, with a narrow focus on neuromodulation for migraine. Its differentiation is the combination of two ultra-thin subcutaneous implants, wireless power and data transfer, and a small external wearable that enables user-activated stimulation. This approach contrasts with drug-based migraine management and positions the company within the broader non-invasive and minimally invasive neuromodulation market. The company’s stated focus on resistant migraine gives it a defined clinical population, while its exploration of cluster headache provides a possible adjacent indication. Salvia is not yet described as a commercial-scale device provider; it remains clinical-stage and is working toward market entry. The $60 million Series B, 29 granted patents, and clinical activity across Europe, Australia, and the United States provide evidence of meaningful development resources. Its competitive position therefore depends on future clinical validation and the ability to translate its compact implant architecture into a practical treatment pathway.

Salvia BioElectronics has followed a staged capital and product-development trajectory since its founding in Eindhoven on Mar 3, 2017. Initial seed financings of approximately $1.52 million in 2018 and $2.06 million in 2019 supported early development, followed by a $31 million Series A on Sep 22, 2020. The company added a 2024 grant round and non-equity assistance before raising $60.1 million in its May 27, 2025 Series B. That financing is the clearest inflection point, moving the company from prototype and clinical-development work toward market introduction. Product development has progressed from early concepts and electronic prototypes to pilot production and clinical studies in multiple regions. MySalvia Therapy now combines implantable neuromodulation hardware with an external wearable, rather than relying on an implant alone. The company reports a team of more than 75 people representing 19 countries, while structured workforce data places it in the 11–50 employee band, creating an unresolved headcount discrepancy.